These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18458821)

  • 61. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
    Taal W; van der Rijt CC; Dinjens WN; Sillevis Smitt PA; Wertenbroek AA; Bromberg JE; van Heuvel I; Kros JM; van den Bent MJ
    J Neurooncol; 2015 Jan; 121(2):365-72. PubMed ID: 25344884
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
    Gonzalez-Aguilar A; Reyes-Moreno I; Peiro-Osuna RP; Hernandez-Hernandez A; Gutierrez-Aceves A; Santos-Zambrano J; Guerrero-Juarez V; Lopez-Martinez M; Castro-Martinez E
    Rev Neurol; 2018 Oct; 67(8):293-297. PubMed ID: 30289152
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adults with newly diagnosed high-grade gliomas.
    Croteau D; Mikkelsen T
    Curr Treat Options Oncol; 2001 Dec; 2(6):507-15. PubMed ID: 12057096
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
    Lassman AB
    CNS Oncol; 2015; 4(5):341-6. PubMed ID: 26544062
    [TBL] [Abstract][Full Text] [Related]  

  • 67. How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
    van den Bent MJ
    Am Soc Clin Oncol Educ Book; 2013; ():114-6. PubMed ID: 23714473
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
    Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P
    Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
    Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
    Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Low-grade oligodendroglioma responds to chemotherapy.
    Mason WP; Krol GS; DeAngelis LM
    Neurology; 1996 Jan; 46(1):203-7. PubMed ID: 8559376
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    Erdem-Eraslan L; Gravendeel LA; de Rooi J; Eilers PH; Idbaih A; Spliet WG; den Dunnen WF; Teepen JL; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; van den Bent MJ; French PJ
    J Clin Oncol; 2013 Jan; 31(3):328-36. PubMed ID: 23269986
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
    Triebels VH; Taphoorn MJ; Brandes AA; Menten J; Frenay M; Tosoni A; Kros JM; Stege EB; Enting RH; Allgeier A; van Heuvel I; van den Bent MJ
    Neurology; 2004 Sep; 63(5):904-6. PubMed ID: 15365146
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anaplastic oligodendroglioma and oligoastrocytoma.
    van den Bent MJ
    Neurol Clin; 2007 Nov; 25(4):1089-109, ix-x. PubMed ID: 17964027
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.
    Iwadate Y; Matsutani T; Shinozaki N; Saeki N
    Anticancer Res; 2011 Dec; 31(12):4475-9. PubMed ID: 22199318
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12.
    Yu T; Kang HC; Lim DH; Kim IH; Chung WK; Suh CO; Choi BO; Cho KH; Cho JH; Kim JH; Park CK; Hong YK; Kim IA
    J Neurooncol; 2015 Feb; 121(3):531-9. PubMed ID: 25391968
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience.
    Ty AU; See SJ; Rao JP; Khoo JB; Wong MC
    Neurology; 2006 Jan; 66(2):247-9. PubMed ID: 16434664
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
    Strowd RE; Abuali I; Ye X; Lu Y; Grossman SA
    J Neurooncol; 2016 Mar; 127(1):165-71. PubMed ID: 26729269
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Aggressive oligodendroglioma: a chemosensitive tumor.
    Cairncross JG; Macdonald DR; Ramsay DA
    Neurosurgery; 1992 Jul; 31(1):78-82. PubMed ID: 1641113
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
    McNamara MG; Jiang H; Lim-Fat MJ; Sahebjam S; Kiehl TR; Karamchandani J; Coire C; Chung C; Millar BA; Laperriere N; Mason WP
    Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.
    Soffietti R; Rudà R; Bradac GB; Schiffer D
    Neurosurgery; 1998 Nov; 43(5):1066-73. PubMed ID: 9802850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.